Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites

Chemical Research in Toxicology

Volumn 22, Issue 2, 2009, Pages 357-368

  Dalvie, Deepak ^a   Scott Obach, R ^b   Kang, Ping ^a   Prakash, Chandra ^b,d   Loi, Cho Ming ^a   Hurst, Susan ^b   Nedderman, Angus ^c   Goulet, Lance ^a   Smith, Evan ^a   Bu, Hai Zhi ^a,e   Smith, Dennis A ^c  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d BIOGEN   (United States)

^e 3D BioOptima Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; [3 [[(4 TERT BUTYLBENZYL)(3 PYRIDINESULFONYL)AMINO]METHYL]PHENOXY]ACETIC ACID; AVASIMIBE; AXITINIB; CAPRAVIRINE; CAPROMORELIN; CELECOXIB; CHEMICAL COMPOUND; CJ 13610; DELAVIRDINE; DRUG METABOLITE; EPLERENONE; GEMCABENE; IRINOTECAN; LASOFOXIFENE; LINEZOLID; MARAVIROC; PAGACLONE; SUNEPITRON; SUNITINIB; TOFIMILAST; TORCETRAPIB; TRAXOPRODIL; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB; ZIPRASIDONE; ZONIPORIDE;

ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DRUG METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIVER CELL; LIVER MICROSOME; PERFORMANCE; PREDICTION; RISK;

DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HEPATOCYTES; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MICROSOMES, LIVER; PHARMACEUTICAL PREPARATIONS;

EID: 62249093071     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx8004357     Document Type: Article

References (51)

1. Baillie, T. A. (2007) Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem. Res. Toxicol. 21, 129-137.
2. Lin, J. H., and Lu, A. Y. H. (1997) Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. 49, 403-449.
3. Baillie, T. A., Cayen, M. N., Fouda, H., Gerson, R. J., Green, J. D., Grossman, S. J., Klunk, L. J., LeBlanc, B., Perkins, D. G., and Shipley, L. A. (2002) Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182, 188-196.
4. Smith, D. A., and Obach, R. S. (2005) Seeing through the MIST: Abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab. Dispos. 33, 1409-1417.
5. Smith, D. A., and Obach, R. S. (2006) Metabolites and safety: What are the concerns, and how should we address them? Chem. Res. Toxicol. 19, 1570-1579.
6. Prueksaritanont, T., Lin, J. H., and Baillie, T. (2006) Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites. Toxicol. Appl. Pharmacol. 217, 143-152.
7. Food and Drug Administration (2008) Guidance for Industry: Safety Testing of Drug Metabolites. FDA, Rockville, MD.
8. Davis-Bruno, K. L., and Atrakchi, A. (2006) A regulatory perspective on issues and approaches in characterizing human metabolites. Chem. Res. Toxicol. 19, 1561-1563.
9. Brandon, E. F. A., Raap, C. D., Meijerman, I., Beijnen, J. H., and Schellens, J. H. M. (2003) An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol. Appl. Pharmcol. 189, 233-246.
10. Pelkonen, O., and Raunio, H. (2005) In vitro screening of drug metabolism during drug development: can we trust the predictions. Expert Opin. Drug Metab. Toxicol. 1, 49-59.
11. Ekins, S. Mäenpää, J. and Wrighton S. A. (1999) In Vitro Metabolism: Subcellar Fractions, in Handbook of Drug Metabolism (Woolf, T. F., Ed.) pp 363-399, Marcel Dekker, Inc. New York.
12. Vermeir, M., Annaert, P., Mamidi, R. N. V. S., Roymans, D., Meuldermans, W., and Mannens, G. (2005) Cell-based models to study hepatic drug metabolism and enzyme induction in humans. Expert Opin. Drug Metab. Toxicol. 1, 75-90.
13. Plant, N. (2004) Strategies for using in vitro screens in drug metabolism. Drug Discovery Today 9, 328-336.
14. Pelkonen, O., Turpeinen, M., Uusitalo, J., Rautio, A., and Raunio, H. (2005) Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic Clin. Pharmacol. Toxicol. 96, 167-175.
15. De Graaf, I. A. M., Van Meijeren, C. E., Pektas, F., and Koster, H. J. (2002) Comparison of in vitro preparations for semi-quantitative prediction of in vivo drug metabolism. Drug Metab. Dispos. 30, 1129-1136.
16. Bu, H.-Z., Pool, W. F., Wu, E. Y., Raber, S. R., Amantea, M. A., and Shetty, B. V. (2004) Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab. Dispos. 32, 689-698.
17. Johnson, K., Shah, A., Jaw-Tsai, S., Baxter, J., and Prakash, C. (2003) Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil in human cytochrome P450 2D6 extensive and poor metabolizers. Drug Metab. Dispos. 31, 76-87.
18. Colizza, K., Awad, M., and Kamel, A. (2007) Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy. Drug Metab. Dispos. 35, 884-897.
19. Prakash, C., Johnson, K. A., and Gardner, M. J. (2008) Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects. Drug Metab. Dispos. 36, 1218-1226.
20. Dalvie, D., Chen, W., Zhang, C., Vaz, A. D., Smolarek, T. A., Cox, L. M., Lin, J., and Obach, R. S. (2008) Pharmacokinetics, metabolism and excretion of torcetrapib a cholesteryl ester transfer protein inhibitor, in humans. Drug Metab. Dispos. 36, 2185-2198.
21. 14C]celecoxib in healthy male volunteers. Drug Metab. Dispos. 28, 308-314.
22. Prakash, C., Kamel, A., Gummerus, J., and Wilner, K. (1997) Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab. Dispos. 25, 863-872.
23. Prakash, C., Cui, D., Baxter, J. G., Bright, G. M., Miceli, J., and Wilner, K. (1998) Metabolism and excretion of a new anxiolytic drug candidate, CP-93,393, in healthy male volunteers. Drug Metab. Dispos. 26, 448-456.
24. 14C] linezolid to healthy human subjects. Drug Metab. Dispos. 29, 1136-1145.
25. 14C ]CPT-11 in cancer patients. Drug Metab. Dispos. 28, 423-433.
26. Yuan, J. J., Yang, D.-C., Zhang, J. Y., Bible, R., Jr., Karim, A., and Findlay, J. W. A. (2002) Disposition of a specific cyclooxy-genase-2 inhibitor, valdecoxib, in human. Drug Metab. Dispos. 30, 1013-1021.
27. 14C]eplerenone after oral administration to humans. Drug Metab. Dispos. 31, 1448-1455.
28. Abel, S., Russell, D., Whitlock, L. A., Ridgway, C. E., Nedderman, A. N. R., and Walker, D. K. (2008) Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br. J. Clin. Pharmacol. 65 (Suppl. 1), 60-67.
29. John, B. A., Brodie, R. R., Baldock, G. A., McBurney, A., Chasseaud, L. F., Jank, P., and Von Nieciecki, A. (2002) Pharmacokinetics and metabolism of the anti-oestrogen droloxifene in female human subjects. Xenobiotica. 32, 699-713.
30. Forgue, S. T., Rudy, A. C., Knadler, M. P., Basson, R. P., Nelson, J. E., Henry, D. P., and Allerheiligen, S. R. (1996) Raloxifene pharmacokinetics in healthy postmenopausal women. Pharm. Res. 13, 429.
31. Ni, L., Allerheiligen, S. R., Basson, R., Knadler, M. P., Latz, J., Geiser, J, Lantz, R., Rash, J., and Henry, D. P. (1996) Pharmacokinetics of raloxifene in men and postmenopausal women volunteers. Pharm. Res. 13, 430.
32. Allerheiligen, S., Geiser, J., Knadler, M. P., Basson, R., Miller, J., Lantz, L., Rash, J., and Draper, M. (1996) Raloxifene (RAL) pharmacokinetics and the associated endocrine effects in premenopausal women treated during the follicular, ovulatory, and luteal phases of the menstrual cycle. Pharm. Res. 13, S430.
33. O'Neill, P. J., Yorgey, K. A., Renzi, N. L., Jr., Williams, R. L., and Benet, L. Z. (1982) Disposition of zomepirac sodium in man. J. Clin. Pharmacol. 22, 470-476.
34. Schneider, W., and Degen, P. H. (1981) Simultaneous determination of diclofenac sodium and its hydroxy metabolites by capillary column gas chromatography with electron-capture detection. J. Chromatogr. 217, 263-271.
35. Doig, M. V., and Clare, R. A. (1991) Use of thermospray liquid chromatography-mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, Lamotrigine. J. Chromatogr. 554, 181-189.
36. Zuidema, J., Hilbers-Modderman, E. S., and Merkus, F. W. (1986) Clinical pharmacokinetics of dapsone. Clin. Pharmacokinet. 11, 299-315.
37. 14C]aminoglutethimide in several animal species and man. Xenobiotica 18, 75-81.
38. Gottlieb, T. B., Thomas, R. C., and Chidsey, C. A. (1972) Pharmacokinetic studies of minoxidil. Clin. Pharmacol Ther. 13, 436-441.
39. Delbressine, L. P., Moonen, M. E., Kaspersen, F. M., Wagenaars, G. N., Jacobs, P. L., Timmer, C. J., Paanakker, J. E., van Hal, H. J., and Voortman, G. (1998) Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin. Drug Invest. 15, 45-55.
40. Wu, W. H., Dicioccio, A. T., Demaio, W., Amorusi, P., Tonelli, A. P., and Mayer, P. R. (1996) Mass balance and pharmacokinetics of zaleplon, a non-benzodiazepine sedative/hypnotic, in man. Pharm. Res. 13, S487.
41. Braeckman, R. A., Granneman, G. R., Rubin, P. R., and Kestenson, J. W. (1989) Phanmacokinetics and metabolism of the new 5-lipoxygenase inhibitor A-64077 after a single oral administration in man (abstr.). J. Clin. Pharmacol. 29, A22.
42. Dalgaard, L., and Larsen, C. (1999) Metabolism and excretion of citalopram in man: identification of O-acyl- and N-glucuronides. Xenobiotica 29, 1033-1041.
43. Ito, T., Yamaguchi, T., Miyazaki, H., Sekine, Y., Shimizu, M., Ishida, S., Yagi, K., Kakegawa, N., Seino, M., and Wada, T. (1982) Pharmacokinetic studies of AD-810, a new antiepileptic compound. Phase I trials. Arzneim. Forsch. 32, 1581-1586.
44. Duggan, D. E., Hare, L. E., Ditzler, C. A., Lei, B. W., and Kwan, K. C. (1977) The disposition of sulindac. Clin. Pharmacol. Ther. 21, 326-335.
45. Haddock, R. E., Johnson, A. M., Langley, P. F., Nelson, D. R., Pope, J. A., Thomas, D. R., and Woods, F. R. (1989) Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites. Acta Psychiatr. Scand. 350 (Suppl), 24-26.
46. 14C]tadalafil. AAPS J. 6, W5308.
47. Kudo, S., and Ishizaki, T. (1999) Pharmacokinetics of haloperidol: an update. Clin. Pharmacokinet. 37, 435-456.
48. Mayol, R. F., Cole, C. A., Luke, G. M., Colson, K. L., and Kerns, E. H. (1994) Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab. Dispos. 22, 304-311.
49. Chen, X., Zhong, D., Liu, D., Wang, Y., Han, Y., and Gu, J. (2003) Determination of ketotifen and its conjugated metabolite in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. Rapid Commun. Mass Spectrom. 17, 2459-2463.
50. Mori, Y., Kuroda, N., Sakai, Y., Yokoya, R, Toyoshi, K., and Baba, S. (1985) Species differences in the metabolism of suprofen in laboratory animals and man. Drug Metab. Dispos. 13, 239-245.
51. Lin, C., Li, Y., McGlotten, J., Morton, J. B., and Symchowicz, S. (1977) Isolation and identification of the major metabolite of albuterol in human urine. Drug Metab. Dispos. 5, 234-238.